Dear Editor,

Invasive molds are the main cause of fungal diseases in immunocompromised patients; these diseases are diagnosed according to the guidelines of the European Organization for Research and Treatment of Cancer/Mycosis Study Group \[[@B1]\]. The mold species specified in these criteria are not clearly defined, but they usually include species with known pathogenic potential, such as *Aspergillus*, *Fusarium*, *Mucorales*, and *Scedosporium* spp. However, nonsporulating molds, especially basidiomycetes (BM), have been reported as emerging pathogens responsible for allergic and invasive diseases, most frequently involving the lungs \[[@B2]\]. As filamentous BM are white nonsporulating molds in culture, conventional identification is problematic. However, with recent advances in sequencing technologies, they have been reported as emerging pathogens \[[@B3]\]. Of the 218 global cases of human pathogenic BM, *Schizophyllum commune* is the most common (52%), followed by *Coprinopsis cinerea* (5.9%), *Emmia lacerata* (5%), and a few cases of *Irpex lacteus* \[[@B2]\].

Although BM are increasingly identified in clinical specimens, little is known about their clinical significance, and Korean cases are rarely reported. We describe five Korean cases of respiratory infections caused by BM among patients admitted to the Seoul St. Mary\'s Hospital, Seoul, Korea, between June 2016 and July 2017. They were three cases of respiratory tract infection caused by *C. cinerea*, *E. lacerate* (formerly *Ceriporia lacerate*), and *I. lacteus* and two cases of suspicious infection caused by *S. commune* and *P. spadiceum*. The Institutional Review Board of Seoul St. Mary\'s Hospital approved the study (approval no. KC19RESI0532) and waived the requirement to obtain informed consent from the patients because this is a retrospective study of clinical cases involving minimal risk to the patients.

The characteristics of the five cases and the fungal morphologies are presented in [Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}, respectively. They were all grown on Sabouraud dextrose agar after two weeks of incubation at 28℃ under light. In all cases, the fungus was identified by sequencing the internal transcribed spacer (ITS)1/ITS2 and the 28S rRNA gene D1/D2 domains \[[@B4]\] using the following primer pairs: pITS1-F (5′-TCCGTAGGTGAACCTGCGG-3′) and pITS1-R (5′-GCTGCGTTCTTCATCGATGC-3′); pITS2-F (5′-GCATCGATGAAGGCAGC-3′) and pITS2-R (5′-TCCTCCGCTTATTATGC-3′); and D1/D2 regions-F (5′-GCATATCAATAAGCGGAAAAG-3′) and D1/D2 regions-R (5′-GGTCCGTGTTTCAAGACGG-3). Then, the sequences were analyzed using Basic Local Alignment Search Tool ([www.ncbi.nlm.nih.gov/BLAST](https://www.ncbi.nlm.nih.gov/BLAST)).

Antifungal susceptibility testing of the five isolates was retrospectively performed in triplicate according to the CLSI-M38 guidelines with a few modifications \[[@B5]\]. The isolates were cultured on potato dextrose agar for five days at 28℃ and then shifted to 37℃ incubation for five days for sporulation. The final inoculum of the homogenized fungal hyphae was adjusted to a density of 2.5--5.0×10^4^ hyphal fragments/mL by adjusting the optical density at 530 nm to 0.13--0.18 using a spectrophotometer (VERSAmax microplate reader, Molecular Devices LLC, CA, USA). The microtiter plate was incubated at 35℃ for 72 hours. Results were obtained only for *S. commune* and *P. spadiceum*. They showed low minimum inhibitory concentrations (MICs) for flucytosine, amphotericin B (AMB), voriconazole (VRC), itraconazole, and ketoconazole and high minimum effective concentrations for micafungin, caspofungin, and anidulafungin. For the remaining three isolates, we could not determine the MICs.

*C. cinerea* is normally found in compost and sewage; however, it rarely causes pulmonary infections, endophthalmitis, endocarditis, and chronic sinusitis \[[@B2]\]. A previous study reported an isolate susceptible to voriconazole and posaconazole but resistant to AMB, caspofungin, and micafungin \[[@B6]\]. Our patient also recovered from fungal pneumonia after treatment with voriconazole and posaconazole.

*E. lacerate*, an agent of white rot on wood, has recently been reported as a human pathogen with low MICs for azoles but high MICs for echinocandins \[[@B7][@B8]\]. To our knowledge, this is the first clinical report of *E. lacerate* in Korea, and the patient recovered from fungal pneumonia after itraconazole treatment.

Another wood-decaying fungus, *I. lacteus*, has been rarely reported. A patient from Austria presenting with a pulmonary abscess was cured following treatment with voriconazole and AMB \[[@B9]\]. Our patient also showed improved chest computed tomography (CT) findings after treatment with voriconazole.

*S. commune* mainly causes sinusitis, allergic bronchopulmonary disease, fungal ball, and asthma. One Korean patient, who had a sino-orbital infection, was successfully cured using voriconazole and AMB \[[@B10]\], which is in line with our susceptibility test results.

*P. spadiceum* has also been isolated from respiratory specimens; however, its pathogenicity is yet to be established \[[@B2]\]. A study on antifungal susceptibility test using two isolates of *P. spadiceum* showed low MICs for AMB, voriconazole, and itraconazole \[[@B3]\], similar to our results.

As BM have been reported as human pathogens only recently and most of these reports mainly detail isolate characteristics, there are few clues to aid in the diagnosis of infection caused by these emerging pathogens. Of our five patients, three showed supportive chest CT findings, such as consolidation, nodular opacity, air-fluid level, and cavitation, while the other two patients showed only pleural effusions that were insufficient to support fungal pneumonia. However, we hypothesized that these two cases were fungal infections because the patients were immunocompromised, and the respiratory tract specimens were negative for acid-fast bacilli, aerobic pathogens, and respiratory viruses. In addition, *S. commune* is the most common BM that causes respiratory tract infections in immunocompromised patients. *P. spadiceum* was isolated from a bronchial wash specimen. Of note, the three patients treated with appropriate antifungal agents survived, while the other two patients who received only antibiotics died.

To our knowledge, this is the first report on respiratory infections caused by BMs in Korea. Although there was insufficient clinical evidence for *S. commune* and *P. spadiceum* infections, it is still important to identify these rare pathogens using molecular techniques to accumulate data. These efforts will help us better understand these infections and develop future diagnostic and therapeutic guidelines.
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![White mold growth in five cases of basidiomycetes inoculated on Sabouraud dextrose agar (SDA) following incubation at 28℃ under light for two weeks; lactophenol cotton blue mount of the mold slide culture on SDA at a magnification of ×400. (A) White colony and (B) hyaline hyphae with clusters of rectangular arthroconidia of *Coprinopsis cinerea*; (C) white colony and (D) spicules (arrows) of *Emmia lacerata*; (E) white colony of *Irpex lacteus*; (F) *I. lacteus* slide showing only hyaline hyphae; (G) white colony and (H) clamp connections (arrows) of *Schizophyllum commune*; (I) white colony of *Porostereum spadiceum*; (J) *P. spadiceum* showing enlarged hyphae (arrows).](alm-40-84-g001){#F1}

###### Characteristics and antifungal susceptibility test results of filamentous basidiomycetes isolated from patients with respiratory tract infection

![](alm-40-84-i001)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          *Coprinopsis cinerea*                         *Emmia lacerata*                              *Irpex lacteus*                                *Schizophyllum commune*                       *Porostereum spadiceum*                       
  --------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------
  Age (yr)/Sex                            22/Male                                       38/Female                                     64/Female                                      66/Female                                     89/Male                                       

  Underlying conditions                   Acute leukemia                                Acute leukemia                                Pulmonary tuberculosis, rheumatoid arthritis   Multiple myeloma Stage III                    Prostate cancer                               

  WBC count /neutrophil/ eosinophil (%)   0.4×10^9^/L/ 68%/ 0%                          8.4×10^9^/L/ 95%/ 0%                          14.9×10^9^/L/ 72.8%/1.3%                       9.0×10^9^/L/ 88%/ 0%                          6.8×10^9^/L/81.6%/2.0%                        

  Diagnosis                               Pneumonia                                     Pneumonia                                     Pneumonia                                      Multi-organ failure                           Pneumonia                                     

  Respiratory symptom                     Cough                                         Occasional hemoptysis                         Cough, sputum, dyspnea                         Dyspnea                                       Dyspnea                                       

  Chest CT finding                        Nodular consolidation with halo\              Atelectasis with pneumonic infiltration       Micronodules and cavities                      Left pleural effusion                         Both pleural effusion                         
                                          Small ill-defined nodular opacities                                                                                                                                                                                                    

  Co-infection                            Not detected                                  *Escherichia coli* in urine                   *Pseudomonas aeruginosa* in sputum             *Candida tropicalis* in urine                 *Escherichia coli* in urine                   

  *Clostridioides difficile* in stool                                                                                                                                                                                                                                            

  Respiratory virus                       Rhinovirus detected                           Rhinovirus detected                           Not detected                                   Not detected                                  Not detected                                  

  Specimen type                           Bronchial washing                             Sputum                                        Bronchial washing                              Sputum                                        Bronchial washing                             

  Treatment                               Voriconazole → Posaconazole                   Itraconazole                                  Voriconazole                                   Antibiotics                                   Antibiotics                                   

  Outcome                                 Recovered                                     Recovered                                     Recovered                                      Death                                         Death                                         

  GenBank accession no                    ITS2 region; MF987832 D1D2 region; MF987831   ITS2 region; MF987826 D1D2 region; MF987825   ITS2 region; MF987830\                         ITS2 region; MF987828 D1D2 region; MF987827   ITS2 region; MF987824 D1D2 region; MF987823   
                                                                                                                                      D1D2 region; MF987829                                                                                                                      

   Antifungal susceptibility test^\*^     Flucytosine                                   NA                                            NA                                             NA                                            2 (MIC, μg/mL)                                \<0.12 (MIC, μg/mL)

  Amphotericin B                          NA                                            NA                                            NA                                             0.125 (MIC, μg/mL)                            0.25 (MIC, μg/mL)                             

  Voriconazole                            NA                                            NA                                            NA                                             0.06--0.125 (MIC, μg/mL)                      0.125--0.25 (MIC, μg/mL)                      

  Itraconazole                            NA                                            NA                                            NA                                             0.125--0.25 (MIC, μg/mL)                      0.25--0.5 (MIC, μg/mL)                        

  Ketoconazole                            NA                                            NA                                            NA                                             0.06--0.125 (MIC, μg/mL)                      0.25--0.5 (MIC, μg/mL)                        

  Micafungin                              NA                                            NA                                            NA                                             \>16 (MEC, μg/mL)                             \>16 (MEC, μg/mL)                             

  Caspofungin                             NA                                            NA                                            NA                                             \>16 (MEC, μg/mL)                             \>16 (MEC, μg/mL)                             

  Anidulafungin                           NA                                            NA                                            NA                                             \>16 (MEC, μg/mL)                             8 (MEC, μg/mL)                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^The results of antifungal agents showing variable MICs in triplicate tests are presented as a range.

Galactomannan was not tested in *Porostereum spadiceum*; galactomannan was not detected in the other four cases.

Abbreviations: NA, not available; MIC, minimum inhibitory concentration; MEC, minimum effective concentration; WBC, white blood cell; CT, computed tomography.
